GlassScriptPhysician profile
Brian S Goldfarb
NPI 1215980503
$2,789.11
in general payments reported to CMS, 2019-2025
25 companies · $664 in 2025
The $664 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $262 · 2021: $42.40 · 2023: $499 · 2024: $715 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $761.38 | 2023-2025 | |
| Novo Nordisk INC | $389.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $271.63 | 2019-2020 | |
| Amgen INC. | $196.08 | 2020-2025 | Evenity, Otezla |
| Abbott Laboratories | $159.76 | 2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $140.96 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.85 | 2024 | |
| Pfizer INC. | $81.47 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $74.04 | 2019-2020 | |
| Glaxosmithkline, LLC. | $70.80 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Zimmer Biomet Holdings, INC. | $67.42 | 2020-2021 | |
| Optinose US, INC. | $65.82 | 2019 | |
| Inspire Medical Systems, INC. | $49.50 | 2023-2024 | Inspire |
| Lilly USA, LLC | $46.59 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.00 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $41.00 | 2019-2020 | |
| Astellas Pharma US INC | $39.47 | 2019-2023 | Veozah |
| Dynavax Technologies Corporation | $30.17 | 2025 | Heplisav-B |
| Aimmune Therapeutics, INC. | $26.14 | 2025 | Zenpep |
| Corium, LLC | $25.44 | 2024 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.16 | 2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $19.51 | 2024 | |
| Gilead Sciences, INC. | $18.05 | 2020 | |
| Hikma Pharmaceuticals USA | $17.97 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Goldfarb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.